FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Part of paid clinical trials in Anaheim, California.

Sponsor
Pfizer
Study ID
NCT06564389
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • PF-07832837 — DRUG
    escalated doses of PF-07832837
  • Placebo — OTHER
    placebo

Study Details

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

Key Dates

Start date
Nov 5, 2024
Status verified
Apr 2026
Primary completion
Jun 2, 2027
Completion
Jun 2, 2027

Study Design

Enrollment
119 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: PF-07832837
    single or multiple doses of PF-07832837 at ascending dose levels
  • Placebo Comparator: placebo
    single or multiple doses of placebo

Primary Outcome Measure

Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD) [ Time Frame: Baseline up to Day 35 ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Anaheim Clinical Trials, LLCAnaheimCalifornia92801-
Miami Dermatology and Laser ResearchMiamiFlorida33133-
Paddington Testing CompanyPhiladelphiaPennsylvania19103-

Find similar trials in Anaheim, CA

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Anaheim Clinical Trials, LLC· Anaheim, CAMiami Dermatology and Laser Research· Miami, FLPaddington Testing Company· Philadelphia, PA

Related Studies